Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + TKI
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cadonilimab + TKI is a combination therapy being investigated for the neoadjuvant treatment of urinary system tumors, specifically urothelial carcinoma and renal cell carcinoma. Cadonilimab (AK104) is a first-in-class humanized tetravalent bispecific antibody that simultaneously targets the programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoints. By blocking both pathways, it aims to enhance anti-tumor immune responses. In this combination, it is paired with a tyrosine kinase inhibitor (TKI), such as sunitinib or pazopanib, which inhibits vascular endothelial growth factor (VEGF) signaling and other pathways involved in tumor angiogenesis and proliferation. This combination is being evaluated by Tongji Hospital in a Phase II trial to assess its efficacy in achieving organ preservation (bladder or kidney) by reducing tumor burden before surgery.
- Brand names
- Kaitani
- Other names
- AK104 + TKIcadonilimab plus TKI
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR (VEGFR family)
Beyond the preview
Go deeper on cadonilimab + TKI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + TKI.